A comprehensive comparison of these GHRH analog research peptides, examining their structural modifications, pharmacokinetic profiles, and applications in growth hormone axis research.
Part of the PeptidesATX Research Hub
Growth hormone-releasing hormone (GHRH) analogs are essential tools for investigating pituitary function and GH axis regulation. CJC (No Dac) and Tesa represent two distinct approaches to GHRH analog design, each with unique structural features that affect their research applications.
Understanding the differences between these compounds is critical for researchers designing studies in neuroendocrine signaling, somatotroph biology, and GH/IGF-1 axis function.
CJC (No Dac) is a truncated GHRH (1-29) with amino acid substitutions and optional DAC for extended duration, while Tesa is the full 44-amino acid GHRH with an N-terminal trans-3-hexenoic acid modification. Both target GHRH-R but differ in structure and pharmacokinetics.
The structural differences between these GHRH analogs determine their stability, receptor interactions, and duration of action.
| Property | CJC (No Dac) | Tesa |
|---|---|---|
| Parent Sequence | GHRH (1-29) | GHRH (1-44) |
| Amino Acid Length | 29 residues | 44 residues |
| Key Modification | 4 amino acid substitutions | Trans-3-hexenoic acid (N-terminal) |
| DPP-IV Resistance | Enhanced via substitutions | Enhanced via modification |
| Duration Extension | DAC variant: albumin binding | Modification-based stability |
| Molecular Weight | ~3368 Da (without DAC) | ~5136 Da |
CJC (No Dac) is based on the biologically active N-terminal 29 amino acids of GHRH, modified for enhanced stability and optional extended duration.
For additional information on CJC (No Dac) in combination studies, see our CJC (No Dac) vs Ipamorlin Comparison.
Tesa consists of the complete 44-amino acid human GHRH sequence with an N-terminal trans-3-hexenoic acid modification.
For detailed Tesa mechanisms, see our Tesa Research Guide.
Both compounds target the GHRH receptor but structural differences may affect signaling dynamics.
| Signaling Aspect | CJC (No Dac) | Tesa |
|---|---|---|
| Target Receptor | GHRH-R | GHRH-R |
| G Protein Coupling | Gs activation | Gs activation |
| Second Messenger | cAMP elevation | cAMP elevation |
| Downstream Effector | PKA activation | PKA activation |
| Duration (no DAC/standard) | Short (minutes to hours) | Intermediate |
| Duration (DAC variant) | Extended (days) | N/A |
The pharmacokinetic profiles differ based on structural modifications and potential albumin binding.
When comparing these compounds, researchers should consider whether acute (pulsatile) or sustained stimulation better models their research question. CJC (No Dac) without DAC and Tesa are both short-acting peptides without an albumin-binding modification (tesamorelin's elimination half-life in people is about 11 minutes per the FDA label; no head-to-head comparison of the two is cited here), while CJC-1295 with DAC binds albumin and remains in circulation for days (Jetté et al., Endocrinology 2005, in rats; Teichman et al., J Clin Endocrinol Metab 2006, in healthy adults).
Selection between these GHRH analogs depends on specific experimental requirements.
CJC (No Dac) and Tesa both serve as valuable GHRH receptor research tools with distinct characteristics:
The choice between these compounds should align with specific research objectives regarding duration, structure, and GH axis investigation goals.
Both are GHRH analogs but differ in structure and duration. CJC (No Dac) is a modified GHRH (1-29) with amino acid substitutions for DPP-IV resistance, while Tesa is the full 44-amino acid GHRH sequence with a trans-3-hexenoic acid modification. CJC (No Dac) with DAC has extended duration via albumin binding.
Comparing these GHRH analogs helps researchers understand how different structural modifications affect receptor binding, signaling kinetics, and duration of action. This comparison informs selection of appropriate compounds for specific GH axis research objectives.
CJC (No Dac) with DAC (Drug Affinity Complex) contains a lysine-linked maleimidopropionic acid that binds to serum albumin, extending its duration of action. CJC (No Dac) without DAC (also called Mod GRF 1-29) has shorter duration, useful for studying acute GHRH receptor responses.
Yes, both compounds target the GHRH receptor (GHRH-R) on pituitary somatotroph cells. They activate the same Gs-cAMP-PKA signaling cascade, but structural differences may affect binding affinity, receptor kinetics, and downstream signaling patterns.
Access research-grade peptides and quality documentation for your laboratory investigations. See our Tesa sourcing guide for supplier details.
CJC (No Dac)/Ipamorlin Blend View Related Research Compounds Certificates of AnalysisDisclaimer: These compounds are intended for laboratory research use only. They are not approved for human or veterinary use. All research must be conducted in accordance with applicable institutional and regulatory guidelines.